TMS Co., Ltd. (TSE: 4891)
Health Care · Biotechnology · JP
¥110.00
+7.84% today · -29.0% 1Y
TMS Co., Ltd. (TSE: 4891) operates in the Biotechnology industry within the Health Care sector. The company is valued at $31.60M and employs 18 people.
Over the last twelve months the share price has lost 29.0%, trading between 92.00 and 166.00.
Tweenvest scores TMS Co., Ltd. across four factors: quality 51/100. Its strongest factor is quality.
4891 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $31.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -15.99
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- ¥166.00
- 52-week low
- ¥92.00
- Avg volume (3M)
- —
- Shares outstanding
- 45.67M
- Employees
- 18
- Next earnings
- —
About TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.
- ISIN
- JP3544960002
- Founded
- 2005
- Listed since
- Nov 22, 2022
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.